Medical Oncologist
HER2-positive cancer treatment
Subcutaneous vs IV Trastuzumab: — Which Is Right for You?
Both subcutaneous and IV trastuzumab deliver the same medicine to the same target. The difference is how long you spend in the day-care unit and how the medicine enters your body. Your oncologist can prescribe either, and the choice often comes down to what fits your life.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Same medicine, different route — Both formulations contain trastuzumab. One is injected under the skin; the other goes into a vein through a drip.
- SC saves significant clinic time — The subcutaneous injection takes only a few minutes. IV trastuzumab can take 30 to 90 minutes depending on the dose.
- Equally effective by clinical evidence — ESMO and NCCN guidelines recognise both routes as equivalent in efficacy for HER2-positive cancer.
- Your preference is a valid input — If both routes are clinically suitable for you, your oncologist will take your daily life and comfort into account.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Subcutaneous trastuzumab is injected under the skin in a few minutes. IV trastuzumab goes into a vein and takes longer — around 90 minutes for your first dose, around 30 minutes for later ones. ESMO guidance supports both as equally effective. The choice is mainly about what fits your life.
What is the difference between subcutaneous and IV trastuzumab?
Subcutaneous (SC) trastuzumab is injected under the skin, usually in the thigh. The injection itself takes only a few minutes, and your overall time in the day-care unit is much shorter than with the drip.
IV trastuzumab goes into a vein through a cannula and a drip. Your first IV infusion takes around 90 minutes so the nurses can watch for reactions. If you tolerate it well, later infusions are given over a shorter time.
Both formulations contain trastuzumab targeting the HER2 protein. The difference is how the medicine reaches your bloodstream, not what it does once it gets there.
What happens during a subcutaneous trastuzumab visit?
You check in with the day-care nurse
Your nurse reviews your recent blood results and confirms you are ready to receive the dose that day.
The fixed-dose vial is prepared
SC trastuzumab uses a single fixed dose for every patient — there is no weight-based calculation, unlike the IV formulation.
A small needle is placed under the skin of your thigh
The nurse cleans the injection site, then inserts a thin needle just below the skin surface.
The injection runs for about five minutes
You sit comfortably while the medicine is delivered. Most people feel only mild pressure or a slight sting at the site.
A short observation period follows
Your nurse monitors you briefly for any injection-site reaction. Once cleared, you are free to leave.
Does the route of administration affect how well trastuzumab works?
Clinical evidence, including the phase III HannaH trial published in The Lancet Oncology, showed that SC trastuzumab was non-inferior to IV trastuzumab on the primary response measure the trial used.
ESMO guidelines list both routes as equivalent options for HER2-positive breast cancer. NCCN guidelines similarly include both without a preference based on efficacy.
Being prescribed SC rather than IV is not a downgrade. It is the same medicine, supported by the same body of evidence.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
Terms your team may use
- Subcutaneous (SC)
- Given under the skin rather than into a vein. The medicine is absorbed through the tissue into the bloodstream.
- Intravenous (IV)
- Given directly into a vein through a cannula and a drip. The medicine enters the bloodstream immediately.
- Loading dose
- The first IV dose, which is higher than the doses that follow. It is given to bring the medicine quickly to a therapeutic level. The SC formulation uses the same fixed dose every cycle and has no separate loading dose.
- Maintenance dose
- The regular, lower dose used for IV trastuzumab after the loading dose has been given.
- HER2
- A protein on the surface of some cancer cells that drives their growth. Trastuzumab works by attaching to HER2 and blocking this signal.
- Day care
- Treatment given and completed on the same day, without an overnight hospital stay. Both SC and IV trastuzumab are administered as day care at CION.
Which route is more likely to suit you?
SC trastuzumab is often preferred by people who work, have young children, or travel a long distance to the clinic. Spending less time in the chair each cycle adds up over a full course of treatment.
IV trastuzumab may suit you better if you have concerns about injections, if your treating team has a clinical reason to start with IV, or if SC trastuzumab is not available at the centre you attend.
Tell your oncologist if one option matters to you and why. Preference is a legitimate clinical consideration, and most oncologists will accommodate it unless there is a specific medical reason not to.
Did you know?
The PrefHer trial asked patients who had received both SC and IV trastuzumab which they would choose for the rest of their treatment.
A large majority chose the subcutaneous route. The main reasons were shorter clinic time and greater convenience — not a difference in how they felt during or after the injection.
Source: PrefHer trial, The Lancet Oncology (2013); ESMO Clinical Practice Guidelines
Explore 75 more Breast Cancer Targeted Medicines topics
Drug Deep Dive: Trastuzumab (Herceptin)
- Adjuvant Trastuzumab: Why Exactly 12 Months After Surgery?
- Diet and Nutrition While on Trastuzumab
- Drug, Food and Supplement Interactions With Trastuzumab
- Fatigue, Chills and Flu-Like Symptoms After a Trastuzumab Infusion
- Fertility, Pregnancy and Contraception on Trastuzumab
- Heart Function and Trastuzumab: Understanding Your ECHO Reports
- Herceptin vs Biosimilar Trastuzumab: Are They Really the Same?
- How Does Trastuzumab Work? The Anti-HER2 Monoclonal Antibody Explained
- How Long Does Trastuzumab Take to Work?
- How Long Will You Stay on Trastuzumab?
- Subcutaneous Trastuzumab vs IV Infusion: Which Suits You Better?
- Tests and Monitoring While You Are on Trastuzumab
- Trastuzumab (Herceptin and biosimilars): The Complete Patient Guide
- Trastuzumab Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Infusion Reactions: What Happens and How They're Managed
- Trastuzumab Myths: 'It's Chemotherapy' and Other Misunderstandings
- Trastuzumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Side Effects: The Complete List and Timeline
- Trastuzumab Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab With Pertuzumab, Chemotherapy and Hormone Therapy
- Trastuzumab in Elderly Patients and Those With Other Illnesses
- When Trastuzumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Trastuzumab? HER2-Positive Breast and Gastric Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab?
- Work, Travel and Daily Life on Trastuzumab
Drug Deep Dive: Palbociclib (Ibrance)
- Diet and Nutrition While on Palbociclib
- Drug, Food and Supplement Interactions With Palbociclib
- Fatigue on Palbociclib: Why It Happens and What Genuinely Helps
- Fertility, Pregnancy and Contraception on Palbociclib
- How Does Palbociclib Work? The CDK4/6 Inhibitor Explained
- How Long Does Palbociclib Take to Work?
- How Long Will You Stay on Palbociclib?
- Low White Cell Count on Palbociclib: Expected, and Rarely Dangerous
- Mouth Sores and Infection Risk on Palbociclib
- Palbociclib (Ibrance, Palbace): The Complete Patient Guide
- Palbociclib Myths: Low Counts, Hair Loss and Stopping Early
- Palbociclib Price in India: Brand, Generic and Monthly Cost
- Palbociclib Side Effects: The Complete List and Timeline
- Palbociclib Success Rate and Survival: An Honest Look at the Numbers
- Palbociclib With Letrozole or Fulvestrant: Understanding Your Combination
- Palbociclib in Early Breast Cancer: Why It Is Not Given After Surgery
- Palbociclib in Elderly Patients and Those With Other Illnesses
- Palbociclib vs Ribociclib vs Abemaciclib: Which CDK4/6 Inhibitor?
- Taking Palbociclib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Palbociclib
- The 21-Days-On, 7-Days-Off Palbociclib Cycle Explained
- When Palbociclib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Palbociclib? Hormone-Receptor-Positive, HER2-Negative Breast Cancer
- Will Insurance or a Government Scheme Pay for Palbociclib?
- Work, Travel and Daily Life on Palbociclib
Drug Deep Dive: Trastuzumab Deruxtecan (Enhertu)
- Diet and Nutrition While on Trastuzumab Deruxtecan
- Drug, Food and Supplement Interactions With Trastuzumab Deruxtecan
- Enhertu Myths: 'It's Just Stronger Herceptin' and Cost Misconceptions
- Enhertu in Breast, Gastric and Lung Cancer: One Drug, Three Diseases
- Fertility, Pregnancy and Contraception on Trastuzumab Deruxtecan
- HER2-Low Breast Cancer: How Enhertu Created an Entirely New Patient Group
- How Does Trastuzumab Deruxtecan Work? The HER2-Directed Antibody-Drug Conjugate Explained
- How Long Does Trastuzumab Deruxtecan Take to Work?
- How Long Will You Stay on Trastuzumab Deruxtecan?
- Interstitial Lung Disease on Enhertu: The Side Effect That Needs Immediate Action
- Low Blood Counts, Hair Loss and Heart Monitoring on Enhertu
- Nausea and Vomiting on Trastuzumab Deruxtecan: Managing a High-Risk ADC
- Tests and Monitoring While You Are on Trastuzumab Deruxtecan
- Trastuzumab Deruxtecan (Enhertu): The Complete Patient Guide
- Trastuzumab Deruxtecan Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Deruxtecan Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Deruxtecan Side Effects: The Complete List and Timeline
- Trastuzumab Deruxtecan Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab Deruxtecan in Elderly Patients and Those With Other Illnesses
- Trastuzumab Deruxtecan vs T-DM1 and Trastuzumab: How ADCs Differ
- When Trastuzumab Deruxtecan Stops Working: Resistance and What Comes Next
- Where Trastuzumab Deruxtecan Fits Alongside Chemotherapy and Hormone Therapy
- Who Is Eligible for Trastuzumab Deruxtecan? HER2-Positive and HER2-Low Breast, Gastric and Lung Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab Deruxtecan?
- Work, Travel and Daily Life on Trastuzumab Deruxtecan
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Can I switch from IV to SC trastuzumab partway through treatment?
Yes, in most cases. Switching routes midway through a course is clinically supported and is done regularly. Your oncologist will confirm there is no reason specific to your situation that makes a switch inadvisable, then arrange the change. You do not need to restart treatment from the beginning. If you are currently on IV and prefer SC, raise it at your next appointment.
Does the SC injection hurt more than the IV drip?
Most people describe the SC injection as a mild sting or pressure at the thigh that lasts only a few minutes. The IV drip requires inserting a cannula into a vein, which some people find more uncomfortable, particularly if their veins are difficult to access. Neither route causes the kind of ongoing discomfort that would normally stop someone from continuing treatment. Tell your nurse if the injection site is particularly sore after you leave, as this can be managed.
Is the dose of SC trastuzumab the same for everyone?
Yes. SC trastuzumab is given as a single fixed dose regardless of body weight, which is different from IV trastuzumab, where the dose is calculated from your weight. This fixed-dose approach was tested in clinical trials and shown to produce reliable medicine levels across a range of body weights. It also simplifies preparation, which is part of why SC visits tend to be shorter.
Will my insurance or hospital scheme cover SC trastuzumab?
Coverage depends on your specific policy and your treating hospital. SC trastuzumab is a newer formulation, and some schemes that covered IV trastuzumab may not yet have updated their approvals. Ask your oncologist's office to verify coverage before your first dose. CDSCO has approved SC trastuzumab for use in India, so the regulatory pathway is in place; the question is your individual scheme.
What side effects are different between SC and IV trastuzumab?
The systemic side effects of trastuzumab — including effects on heart function, which your team monitors throughout treatment — are the same for both routes. Where they differ is at the site of administration. SC injections can cause localised redness, swelling, or discomfort at the thigh. IV infusions occasionally cause infusion reactions during the drip, which is why your first IV dose is given slowly with close monitoring. Report any injection-site reaction to your team at your next visit, or sooner if it is spreading or worsening.
If both are equally effective, why does it matter which I get?
It matters because the total time spent receiving treatment over months is a real factor in a person's life. SC trastuzumab can reduce chair time significantly across a full treatment course. Comfort, convenience, and the ability to maintain work or family commitments are not trivial — they affect whether someone can sustain treatment as planned. Asking for the route that fits your life better is a reasonable and practical question to put to your oncologist.